Search

Your search keyword '"Term (time)"' showing total 409 results
Start Over Descriptor "Term (time)" Topic business.industry Journal value in health
409 results on '"Term (time)"'

1. PIN120 The IMPACT of LONG-TERM Exposure to PM2.5, PM10 and NO2 Air Pollutants on the Age-Adjusted Mortality RATE of COVID-19 Based on the Example of Poland

Author

A. Musialek and A. Nosowicz

Subjects
2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Air pollutants, business.industry, Health Policy, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Environmental health, Public Health, Environmental and Occupational Health, Age-Adjusted Mortality Rate, Medicine, business, Article, Term (time)
Published
2020

3. PSS16 Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers' Compensation for Employees with Osteoarthritis in the United States

Author

I.A. Beren, Richard A. Brook, and Nathan L. Kleinman

Subjects
business.industry, Health Policy, media_common.quotation_subject, Rheumatoid arthritis, Public Health, Environmental and Occupational Health, Medicine, Workers' compensation, Demographic economics, Payment, business, medicine.disease, media_common, Term (time)
Published
2021

4. PCN25 Systematic Literature Review of Treatment Patterns, Long-Term Efficacy, and Safety of Dasatinib Therapy for Patients with Chronic Myeloid Leukemia

Author

A. Kee, S. Harricharan, Anna Forsythe, Ronda Copher, J. Brokars, and S. Grieve

Subjects
Oncology, Dasatinib, medicine.medical_specialty, Systematic review, business.industry, Health Policy, Internal medicine, Public Health, Environmental and Occupational Health, Medicine, Myeloid leukemia, business, medicine.drug, Term (time)
Published
2021

5. PCV2 Real-World Outcomes of Antithrombotic Therapies in Patients with Coronary Artery Disease That Require Long-Term Oral Anticoagulation

Author

A. Osterland, R.J. Widmer, and P.J. Godley

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Real world outcomes, medicine.disease, Term (time), Coronary artery disease, Antithrombotic, medicine, In patient, Intensive care medicine, business, Oral anticoagulation
Published
2021

6. PCN11 The potential long-term comparative effectiveness of larotrectinib vs. lenvatinib or sorafenib for treatment of NTRK fusion-positive metastatic thyroid cancer

Author

J.J. Carlson, Kangho Suh, F. Xia, Todd Williamson, and Sean D. Sullivan

Subjects
Oncology, Sorafenib, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Term (time), chemistry.chemical_compound, chemistry, Internal medicine, medicine, Metastatic thyroid cancer, Lenvatinib, business, medicine.drug
Published
2021

7. PSY26 Healthcare Costs, Resource Utilization, and Adverse Events Associated with Long-term Oral Corticosteroid Use in Patients with Systemic Lupus Erythematosus in the United States

Author

Mei Sheng Duh, J. Vu, Maral DerSarkissian, Y.M. Gu, Christopher F. Bell, J. Benson, M.J. Wang, and S. Huang

Subjects
medicine.medical_specialty, business.industry, Health Policy, Health care, Public Health, Environmental and Occupational Health, Medicine, In patient, Corticosteroid use, business, Intensive care medicine, Adverse effect, Resource utilization, Term (time)
Published
2021

8. PND9 Exploring Serious Adverse Events Associated With Hospitalizations in a Long-term, Phase 3, Open-Label, Repeat-Dose, Safety Study of Diazepam Nasal Spray for Patients With Epilepsy

Author

M. Sperling, R.E. Hogan, A.L. Rabinowicz, James W. Wheless, D. Tarquinio, E. Carrazana, N. Fountain, and Dennis J. Dlugos

Subjects
business.industry, Health Policy, medicine.medical_treatment, Public Health, Environmental and Occupational Health, medicine.disease, Repeat dose, Term (time), Epilepsy, Nasal spray, Anesthesia, medicine, Open label, business, Adverse effect, Diazepam, medicine.drug
Published
2021

11. PCV27 COST-EFFECTIVENESS OF INSERTABLE CARDIAC MONITORS VERSUS STANDARD OF CARE OR SHORT-TO-LONG-TERM ECG MONITORING TO IDENTIFY ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE

Author

Matthew R. Reynolds, Sarah C Rosemas, K K Witte, L. Sawyer, Shadi Yaghi, F. Grimsey Jones, Paul D. Ziegler, Rachelle E Kaplon, and Suneet Mittal

Subjects
medicine.medical_specialty, Standard of care, Cost effectiveness, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Atrial fibrillation, medicine.disease, Term (time), Cryptogenic stroke, Ecg monitoring, Internal medicine, medicine, Cardiology, Cardiac monitors, business
Published
2020

13. PDB6 LONG-TERM ASSOCIATION OF OBSERVED VERSUS PREDICTED MICRO- AND MACROVASCULAR COMPLICATIONS IN TYPE 1 DIABETES MELLITUS: EXTERNAL VALIDATION OF THE CORNERSTONE DIABETES SIMULATION MODEL (CDSM)

Author

D. Moldaver, M. Afonso, J. Bartelt-Hofer, Daniel T. Grima, M. Ainslie-Garcia, and L. Sauriol

Subjects
Type 1 diabetes, medicine.medical_specialty, business.industry, Health Policy, Diabetes mellitus, Internal medicine, Public Health, Environmental and Occupational Health, medicine, External validation, medicine.disease, business, Term (time)
Published
2019

14. PGI58 A STUDY OF LONG TERM HOSPITALIZATION COSTS IN PATIENTS WITH ULCERATIVE COLITIS USING GERMAN CLAIMS DATA

Author

M. Ghiani, Bernd Bokemeyer, David Myers, Ulf Maywald, Dominik Naessens, Thomas Wilke, and Péter Takács

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Ulcerative colitis, language.human_language, Term (time), German, Claims data, medicine, language, In patient, Intensive care medicine, business
Published
2019

15. PDB51 PREVENTION AS A PUBLIC HEALTH MEASURE: LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF A POPULATION-BASED IODINE DEFICIENCY DISEASES PREVENTION PROGRAM

Author

Gaby Sroczynski, Wilhelm Oberaigner, Nikolai Mühlberger, Uwe Siebert, J. Lazarus, Igor Stojkov, Ursula Rochau, Annette Conrads-Frank, E. Koukkou, Henry Voelzke, Monika Schaffner, T. Ittermann, and V. Qerimi

Subjects
medicine.medical_specialty, Cost effectiveness, business.industry, Health Policy, Environmental health, Public health, Public Health, Environmental and Occupational Health, Measure (physics), medicine, Population based, Iodine deficiency diseases, business, Term (time)
Published
2019

18. PUK14 ACUTE Renal Failure during COVID-19 and Its LONG-TERM IMPACT on Health System

Author

S. Boeger, R. Pohlmeier, E. Busink, J. Petrovic, F. Kircelli, and C. Apel

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Health Policy, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Public Health, Environmental and Occupational Health, medicine, Intensive care medicine, business, Article, Term (time)
Published
2020

19. PDB28 MODEL-Based LONG-TERM Cost-Effectiveness of Once-Weekly Semaglutide Compared with Other GLP-1 Receptor Agonists in Type 2 Diabetes: A Systematic Literature Review

Author

R. Zhen, H. Shi, Hao Hu, and Ling Yang

Subjects
Oncology, medicine.medical_specialty, Cost effectiveness, business.industry, Health Policy, Semaglutide, Public Health, Environmental and Occupational Health, Once weekly, Type 2 diabetes, medicine.disease, Term (time), Systematic review, Internal medicine, medicine, business, Glucagon-like peptide 1 receptor
Published
2020

20. PRS9 LONG-TERM IMPACT of PRIOR Chronic Obstructive Pulmonary Disease Exacerbations on Healthcare Resource Utilisation (HCRU) and Related Costs: An Observational Study (SHERLOCK)

Author

Ulf Holmgren, Mintu Nath, Hana Müllerová, Amanda J Lee, E. de Nigris, John Haughney, and Bo Ding

Subjects
medicine.medical_specialty, Resource (biology), business.industry, Health Policy, Health care, Public Health, Environmental and Occupational Health, medicine, Pulmonary disease, Observational study, Intensive care medicine, business, Term (time)
Published
2020

21. PCN348 Long-Term Healthcare Resource Utilization and Costs Associated with Patients Treated with Nivolumab for Advanced Non-Small Cell Lung Cancer

Author

R. Jolivel, Anne-Françoise Gaudin, R. Corre, C.Y. Calvet, Christos Chouaid, Jean-Baptiste Assié, V. Grumberg, B. Jouaneton, François-Emery Cotté, and M. Giaj-Levra

Subjects
Oncology, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Term (time), Internal medicine, Health care, medicine, Non small cell, Nivolumab, business, Lung cancer, Resource utilization
Published
2020

22. IN2 A Model-Based Estimation of the Cost-of-Illness Associated with Neisseria gonorrhoea in England and the USA: Assessing the Potential Impact of Antimicrobial Resistance and Long-Term Health Problems

Author

E. Beck, A.C. Peultier, L. Arnold, and Jane Whelan

Subjects
Estimation, Potential impact, biology, business.industry, Health Policy, Public Health, Environmental and Occupational Health, biology.organism_classification, Term (time), Health problems, Antibiotic resistance, Environmental health, Cost of illness, Medicine, Neisseria, business
Published
2020

23. PDB32 A LONG-TERM Cost-Effectiveness Analysis of Treatments for Type 2 Diabetes in Portugal: Once-Weekly Semaglutide 1 MG Versus Once-Daily Empagliflozin 25 MG

Author

C. Costa, N. Hallén, B. Hunt, and D. Carvalho

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Semaglutide, Public Health, Environmental and Occupational Health, Once weekly, Type 2 diabetes, Cost-effectiveness analysis, medicine.disease, Term (time), Empagliflozin, Medicine, Once daily, business
Published
2020

24. PDB36 LONG-TERM Cost-Effectiveness Analyses of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Type 2 Diabetes in Three Countries: Bosnia and Herzegovina, Greece, and Slovenia

Author

N. Hallén, S. Liatis, A. Thanopoulou, A. Ogrič Lapajne, I. Ioannidis, D. Djekic, and B. Hunt

Subjects
Cost effectiveness, business.industry, Health Policy, Semaglutide, Public Health, Environmental and Occupational Health, Empagliflozin, medicine, Once weekly, Type 2 diabetes, medicine.disease, business, Term (time), Demography
Published
2020

26. PDG18 LONG-TERM Cost-Effectiveness of the Sofosbuvir-Based Directing-Acting Antivirals in Treating Patients with Chronic Hepatitis C (CHC) in China: From a Healthcare Payer’S Perspective

Author

J. Zhao, M. Hu, and J. Xie

Subjects
medicine.medical_specialty, Sofosbuvir, Cost effectiveness, business.industry, Health Policy, Perspective (graphical), Public Health, Environmental and Occupational Health, Healthcare payer, Term (time), Chronic hepatitis, Medicine, business, China, Intensive care medicine, medicine.drug
Published
2020

27. PMS32 LONG–TERM PAIN Management Pathways of Patients with Osteoarthritis of the HIP/Knee before Joint Replacement — a Retrospective Cohort Study Based on German Health Claims DATA

Author

M. Schild, W. Galetzka, U. Müller, A. Mocek, H Gothe, and T.C. Ploner

Subjects
medicine.medical_specialty, business.industry, Joint replacement, Health Policy, medicine.medical_treatment, Public Health, Environmental and Occupational Health, Retrospective cohort study, Osteoarthritis, Pain management, medicine.disease, language.human_language, Term (time), German, Health claims on food labels, language, Physical therapy, Medicine, business
Published
2020

28. PND15 LONG-TERM COST-EFFECTIVENESS OF LASMIDITAN, UBROGEPANT AND RIMEGEPANT FOR TREATMENT OF ACUTE MIGRAINE

Author

David Rind, Steven D. Pearson, S.J. Atlas, T.A. Lee, Daniel R. Touchette, Richard H. Chapman, Foluso Agboola, and M. Joshi

Subjects
medicine.medical_specialty, Acute migraine, business.industry, Cost effectiveness, Health Policy, Public Health, Environmental and Occupational Health, Lasmiditan, Term (time), chemistry.chemical_compound, Rimegepant, chemistry, Ubrogepant, medicine, Intensive care medicine, business
Published
2020

29. PDG12 THE LONG-TERM COST-EFFECTIVENESS OF VILDAGLIPTIN+ METFORMIN THERAPY RELATIVE TO COMPARATOR SULFONYLUREA+ METFORMIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN CHINA

Author

J. Xu

Subjects
Oncology, medicine.medical_specialty, business.industry, Cost effectiveness, medicine.drug_class, Health Policy, Public Health, Environmental and Occupational Health, Type 2 diabetes, medicine.disease, Sulfonylurea, Metformin, Term (time), Internal medicine, medicine, In patient, Vildagliptin, business, medicine.drug
Published
2020

33. PCN121 LONG-TERM COST-EFFECTIVENESS MODELING COMPARING MATURITY OF DATA CUTS: A COMPARISON BETWEEN COST-EFFECTIVENESS OF NIVOLUMAB VS EVEROLIMUS IN SECOND LINE RENAL CELL CARCINOMA USING 2- OR 3-YEAR FOLLOW UP CHECKMATE-025 DATA

Author

H. Sandhu and A. Berardi

Subjects
Oncology, medicine.medical_specialty, Everolimus, Cost effectiveness, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Checkmate, medicine.disease, Maturity (finance), Term (time), Second line, Renal cell carcinoma, Internal medicine, medicine, Nivolumab, business, medicine.drug
Published
2020

35. PRS23 THE LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING REGIMENS ON COST BURDEN TO THE HEALTHCARE SYSTEM AND FAMILIES OF PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS IN INDONESIA

Author

Amit Dhir, Laurent Metz, C.F. Chiou, H. Mansjur, Ravi Potluri, A. Mpobela Agnarson, C. Kambili, and U.C. Insani

Subjects
medicine.medical_specialty, business.industry, Health Policy, Drug resistant tuberculosis, Public Health, Environmental and Occupational Health, Cost burden, Term (time), chemistry.chemical_compound, chemistry, Medicine, Bedaquiline, business, Intensive care medicine, Healthcare system
Published
2020

37. PIN48 THE LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING REGIMENS ON COST BURDEN OF DRUG-RESISTANT TUBERCULOSIS IN INDIA

Author

L. Raute, M.A. Agnarson, N. Shah, L. Metz, H. Bhandari, Ravi Potluri, A. Kumar, A. Dhir, C. Kambili, and V. Gupta

Subjects
chemistry.chemical_compound, medicine.medical_specialty, chemistry, business.industry, Health Policy, Drug resistant tuberculosis, Public Health, Environmental and Occupational Health, Medicine, Bedaquiline, business, Intensive care medicine, Cost burden, Term (time)
Published
2019

38. PRO50 THE ECONOMIC BURDEN OF SHORT-TERM ADVERSE EVENTS ASSOCIATED WITH THE CHOP CHEMOTHERAPY REGIMEN IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN EUROPEAN COUNTRIES: A COMPREHENSIVE LITERATURE REVIEW

Author

Crystal Watson, S. Duff, J. Worrall, R. Beckerman, and Arie Barlev

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Lymphoproliferative disorders, CHOP, medicine.disease, Chemotherapy regimen, Term (time), medicine, In patient, Adverse effect, business
Published
2019

39. PMH16 LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION

Author

N. Boyer, Foluso Agboola, David Rind, N. Fluetsch, Brian Talon, Daniel R. Touchette, Varun M. Kumar, K. Fazioli, Bob G. Schultz, and S.J. Atlas

Subjects
medicine.medical_specialty, Esketamine, Cost effectiveness, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine, medicine.disease, Intensive care medicine, business, Treatment-resistant depression, Term (time), medicine.drug
Published
2019

40. PMD6 COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A DUTCH HEALTHCARE SYSTEM PERSPECTIVE

Author

C. Perez Vives, O. Planas, J.C. Elvira, X. Puig, J. Belda, J. Placeres, and D. O'Boyle

Subjects
Cost consequences, business.industry, Health Policy, medicine.medical_treatment, Perspective (graphical), Public Health, Environmental and Occupational Health, Intraocular lens, Cataract surgery, Term (time), Nd:YAG laser, medicine, Capsulotomy, Optometry, business, Selection (genetic algorithm)
Published
2019

46. PDB45 EVALUATING THE SHORT-TERM COST-UTILITY OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE U100 IN BASAL-BOLUS REGIMENS FOR TYPE 2 DIABETES IN CHINA

Author

Luwen Shi, S. Han, L.Y. Zheng, H.K. Sun, and P.X. Dong

Subjects
Oncology, Insulin degludec, medicine.medical_specialty, Insulin glargine, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Basal bolus, Type 2 diabetes, medicine.disease, Term (time), Cost utility, Internal medicine, medicine, business, medicine.drug
Published
2019

47. PGI5 LONG TERM ECONOMIC VALUE OF TIGHT CONTROL WITH ADALIMUMAB-BASED TREATMENT IN CROHN'S DISEASE: THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Author

Luisa Arueira Chaves, RF dos Santos, R. Saad-Hossne, Roseli Peres Moreira, and W. J. Lee

Subjects
Crohn's disease, Actuarial science, business.industry, Health Policy, Perspective (graphical), Control (management), Public Health, Environmental and Occupational Health, medicine.disease, Public healthcare, Term (time), Value (economics), Adalimumab, Medicine, business, medicine.drug
Published
2019

48. PMH54 - PATTERNS OF LONG-TERM CUSTODIAL CARE IN PARKINSON DISEASE PSYCHOSIS

Author

K. Grady, Y. Peng, D.T. Gilbertson, M. Irfan, S. Li, H. Yan, J.B. Wetmore, and A. Shim

Subjects
Psychosis, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Custodial care, medicine, Disease, medicine.disease, business, Psychiatry, Term (time)
Published
2018

50. PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC

Author

Monika Russel-Szymczyk, Barnaby Hunt, K. Rychna, J. Pöhlmann, and W. Parekh

Subjects
Czech, Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Basal insulin, Public Health, Environmental and Occupational Health, Cost-effectiveness analysis, Type 2 diabetes, medicine.disease, language.human_language, Term (time), language, Medicine, business
Published
2018

Catalog

Books, media, physical & digital resources
See catalog results